Skip to content

Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.

Ultrasound Guided Serratus Anterior Plane Block Versus Thoracic Paravertebral Block in Emergency Department Rib Fracture

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04554186
Enrollment
60
Registered
2020-09-18
Start date
2020-09-22
Completion date
2021-01-15
Last updated
2020-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Rib Fractures

Keywords

Fracture rib, TPVB, SAPB

Brief summary

Compare between serratus anterior plane block and thoracic Paravertebral block in analgesia for patients with multiple rib fractures

Detailed description

The study will be conducted in a prospective randomised controlled. Patients will be allocated into three groups Control group: The patient will receive fentanyl patch 50 microgram TPVB group: The patient will receive thoracic vertebral plane lock 0.4ml/kg bupivacaine 0.1 25% will be administered. For continuous infusion catheter will be inserted . Then a rate of 7ml / hour to max 10 ml / hour of bupivacaine 0.0625% SAPB group,: Patient will receive serratus anterior plane block 0.4ml / kg bupivacaine 0.125% will be injected to open the space then a catheter will be advanced For continuous infusion of 0.0625 % bupivacaine at 7 ml / hour

Interventions

PROCEDURESerratus anterior plane block

Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound

PROCEDUREThoracic Paravertebral block

Injection of bupivacaine in the thoracic Paravertebral space using ultrasound

PROCEDUREControl

Place a fentanyl patch 50 microgram

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* ASA 1\_3 Age 18\_60 Unilateral fracture ribs

Exclusion criteria

* Drug allergy Morbid obese Opioid dependence Patients refuse

Design outcomes

Primary

MeasureTime frameDescription
VAS score24 hourVisual analogue pain score describe by the patient

Secondary

MeasureTime frameDescription
Total analgesic consumption24 hourTotal opioid consume by the patient in 24 hour

Countries

Egypt

Contacts

Primary ContactAhmed G Shehata, Master
ahmedgamalicu@gmail.com1067622270
Backup ContactOmyma M Shehata, MD
Omyma.shehata44@yahoo.com1061762894

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026